SCHEMBL5568376

SCHEMBL5568376

CS(=O)(=O)N1CCC(N)(CO)CC1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 10/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CYP2C19 P33261 4/20 0.39
NEK2 P51955 1/20 0.39
CYP2C9 P11712 4/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
CYP3A4 P08684 5/20 0.37
CYP1A2 P05177 2/20 0.37
ALDH1A1 P00352 2/20 0.37
HIF1A Q16665 2/20 0.37
USP2 O75604 1/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37
TSHR P16473 1/20 0.36
TP53 P04637 1/20 0.34
ALOX15 P16050 2/20 0.34
HRH3 Q9Y5N1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23345002 0.82 CYP2D6 (0.44) CYP2D6SMN1; SMN2CYP2C19NEK2CYP2C9
SCHEMBL18049865 0.79 CYP2D6 (0.46) CYP2D6SMN1; SMN2CYP2C19NEK2CYP2C9
SCHEMBL14417823 0.78 CYP2D6 (0.44) CYP2D6SMN1; SMN2CYP2C19NEK2CYP2C9
SCHEMBL3782563 0.74 CYP2D6 (0.44) CYP2D6SMN1; SMN2CYP2C19NEK2CYP2C9
SCHEMBL17501169 0.72 CYP2D6 (0.43) CYP2D6SMN1; SMN2CYP2C19NEK2CYP2C9
SCHEMBL13594764 0.72 CYP2D6 (0.46) CYP2D6SMN1; SMN2CYP2C19NEK2CYP2C9
SCHEMBL7396980 0.72 CYP1A2 (0.32) CYP1A2
SCHEMBL20847066 0.71 CYP2D6 (0.39) CYP2D6SMN1; SMN2CYP2C19NEK2CYP2C9
SCHEMBL17970231 0.70 ALDH1A1 (0.44) CYP2D6SMN1; SMN2CYP2C19NEK2CYP2C9
SCHEMBL23995668 0.69 CYP2D6 (0.41) CYP2D6SMN1; SMN2CYP2C19NEK2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7268150-B2 2-cyano-4-fluoropyrrolidine derivative or its salt YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 2007-09-11 US disclosed
US-7268150-B2 2-cyano-4-fluoropyrrolidine derivative or its salt YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 2007-09-11 US disclosed
US-7268150-B2 2-cyano-4-fluoropyrrolidine derivative or its salt YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 2007-09-11 US disclosed
CN-1312127-C 2-cyano-4-fluoropyrrolidine derivative or its salt YAMANOUCHI PHARMA CO LTD (JP) 2007-04-25 CN disclosed
CN-1665785-A 2-cyano-4-fluoropyrrolidine derivative or its salt YAMANOUCHI PHARMA CO LTD (JP) 2005-09-07 CN disclosed
US-20050176771-A1 2-Cyano-4-fluoropyrrolidine derivative or its salt ASTELLAS PHARMA INC. (JP) 2005-08-11 US disclosed
EP-1541551-A1 2-CYANO-4-FLUOROPYRROLIDINE DERIVATIVE OR ITS SALT YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176771-A1 2-Cyano-4-fluoropyrrolidine derivative or its salt DPP4, DPP7, DPP9 CYP2D6 3089/4885SMN1; SMN2 2483/4885CYP2C19 3168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.